Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective
JCO Oncology Practice · 2023
DOI: 10.1200/op.22.00447 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2023. Verfasst von Minkyoung Yoo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE: Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy-tyrosine kinase inhibitor/immunotherapy drug combinations and sunitinib using public payer acquisition costs in the United States. METHODS: We constructed a decision model with a 10-year time horizon. The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ipilimumab (NI), nivolumab + cabozantinib, lenvatinib + pembrolizumab, and sunitinib. The effectiveness outcome in our model was quality-adjusted life-years (QALYs) with utility values on the basis of the published literature. Costs included drug acquisition costs and costs for management of grade 3-4 drug-related adverse events. We used a partitioned survival model in which patients with mRCC transitioned between three health states (progression-free, progressive disease, and death) at monthly intervals on the basis of parametric survival function estimated from published survival curves. To determine cost-effectiveness, we constructed incremental cost-effectiveness ratios (ICERs) by dividing the difference in cost by the difference in effectiveness between nondominated treatments. RESULTS: The least expensive treatment was sunitinib ($357,948 US dollars [USD]-$656,100 USD), whereas the most expensive was either lenvatinib + pembrolizumab or pembrolizumab + axitinib ($959,302 USD-$1,403,671 USD). NI yielded the most QALYs (3.6), whereas avelumab + axitinib yielded the least (2.5). NI had an incremental ICER of $297,465 USD-$348,516 USD compared with sunitinib. In sensitivity analyses, this ICER fell below $150,000 USD/QALY if the initial 4-month cost of NI decreased by 22%-38%. CONCLUSION: NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.
- Informatics Decision Enhancement and Surveillance (IDEAS) Center, VA Salt Lake City Healthcare System, Salt Lake City, UT.
- University of Utah School of Medicine, Salt Lake City, UT.
- Department of Economics, University of Utah, Salt Lake City, UT.
- Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
- Huntsman Cancer Institute, Salt Lake City, UT.
ORCID-Profile: Minkyoung Yoo, Zachary Cutshall, Maura Dougherty, Manish Kohli
Zitieren
APA
Yoo, M., Nelson, R. E., Cutshall, Z., Dougherty, M., & Kohli, M. (2023). Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO Oncology Practice. https://doi.org/10.1200/op.22.00447
Vancouver
Yoo M, Nelson RE, Cutshall Z, Dougherty M, Kohli M. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO Oncology Practice. 2023. doi:10.1200/op.22.00447
BibTeX
@article{Yoo2023,
author = {Yoo, Minkyoung and Nelson, Richard E and Cutshall, Zachary and Dougherty, Maura and Kohli, Manish},
title = {Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective},
journal = {JCO Oncology Practice},
year = {2023},
doi = {10.1200/op.22.00447}
}
EUVIMED